SkinBioTherapeutics PLC Extension of Research Contract (8748F)
May 23 2017 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 8748F
SkinBioTherapeutics PLC
23 May 2017
SkinBioTherapeutics plc
(the "Company")
Extension of research contract with University of Manchester
SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that, as envisaged in the
Company's Admission Document dated 29 March 2017, it has agreed an
eight month extension to its research contract with the University
of Manchester to June 2018. This contract extension includes
provision for the appointment of a second technician to the
Company. This will increase the Company's ability to develop its
SkinBiotix(R) platform.
Furthermore, the Company announces that it has recently
demonstrated activity of SkinBiotix(R) at a range of doses in human
skin models, and also completed the design of two human safety
trials. If successful, these trials will allow the technology to be
labelled 'dermatologically tested' for its cosmetic
application.
Dr. Catherine O'Neill, CEO of SkinBioTherapeutics, said:
"We are making progress in our research, and the extension and
expansion of our contract with the University of Manchester will
allow meaningful progression across the Company. We are pleased
with the progress of SkinBiotix, and are confident that it remains
on track.
"As a team, we have nurtured relationships with industry
stakeholders for many years. Since our IPO, we have continued to
ensure potential commercial partners are aware of the capabilities
of the SkinBiotix platform."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468 2760
Dr. Catherine O'Neill, CEO
Douglas Quinn, CFO
Cairn Financial Advisers LLP Tel: +44 (0) 20 7213 0880
Tony Rawlinson / Emma Earl / Richard
Nash
Turner Pope Investments Tel: +44 (0) 20 3621 4120
Ben Turner / James Pope
Instinctif Partners Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Alex Shaw SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTEALSAALAXEFF
(END) Dow Jones Newswires
May 23, 2017 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024